RT Journal Article
SR Electronic
T1 Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron variant JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.11.24304075
DO 10.1101/2024.03.11.24304075
A1 de Prost, Nicolas
A1 Audureau, Etienne
A1 Guillon, Antoine
A1 Handala, Lynda
A1 Préau, Sébastien
A1 Guigon, Aurélie
A1 Uhel, Fabrice
A1 Hingrat, Quentin Le
A1 Delamaire, Flora
A1 Grolhier, Claire
A1 Tamion, Fabienne
A1 Moisan, Alice
A1 Darreau, Cédric
A1 Thomin, Jean
A1 Contou, Damien
A1 Henry, Amandine
A1 Daix, Thomas
A1 Hantz, Sébastien
A1 Saccheri, Clément
A1 Giordanengo, Valérie
A1 Pham, Tài
A1 Chaghouri, Amal
A1 Bay, Pierre
A1 Pawlotsky, Jean-Michel
A1 Fourati, Slim
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/03/13/2024.03.11.24304075.abstract
AB A notable increase in severe cases of COVID-19, with significant hospitalizations due to the emergence and spread of JN.1 was observed worldwide in late 2023 and early 2024. During the study period (November 2022-January 2024), 56 JN.1- and 126 XBB-infected patients were prospectively enrolled in 40 French intensive care units. JN.1-infected patients were more likely to be obese (35.7% vs 20.8%; p=0.033) and less frequently immunosuppressed than others (20.4% vs 41.4%; p=0.010). JN.1-infected patients required invasive mechanical ventilation support in 29.1%, 87.5% of them received dexamethasone, 14.5% tocilizumab and none received monoclonal antibodies. Day-28 mortality of JN.1-infected patients was 14.6%.Competing Interest StatementS.F. has served as a speaker for GlaxoSmithKline, AstraZeneca, MSD, Pfeizer, Cepheid and Moderna; J.-M.P. has served as an advisor or speaker for Abbvie, Arbutus, Assembly Biosciences, Gilead and Merck; E.A. has received fees for lectures from Alexion, Sanofi, Gilead and Pfizer. His hospital has received research grant from Pfizer, MSD and Alexion. D.D. served as an advisor for Gilead-Sciences, ViiV Health care, and Merck. N.D.P has served as an advisor or speaker for Moderna and AstraZeneca. Other authors and investigators have no conflict of interest to disclose.Funding StatementThis work was supported by the EMERGEN consortium ANRS Maladies Infectieuses Emergentes (ANRS0153). This study has been labeled as a National Research Priority by the National Orientation Committee for Therapeutic Trials and other researches on Covid-19 (CAPNET). The investigators would like to acknowledge ANRS Emerging infectious diseases for their scientific support, the French Ministry of Health and Prevention and the French Ministry of Higher Education, Research and Innovation for their funding and support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Comite de Protection des Personnes Sud-Mediterranee I (N EudraCT/ID-RCB: 2021-A02914-37).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors